secwatch.observer — SEC 8-K summary
======================================

Issuer:     Entrada Therapeutics, Inc. (TRDA)
CIK:        0001689375
Form:       8-K
Filed at:   2023-09-29T23:59:59+00:00
Accession:  0001104659-23-105351
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Entrada Therapeutics enters into $150M at-the-market offering agreement with Cowen
--------------------------------------------------------------------------------

- Entered into sales agreement with Cowen and Company for at-the-market offering of up to $150M in common stock.
- Cowen will receive a commission of up to 3.0% of gross sales proceeds; Company not obligated to sell any shares.
- Offering made under existing effective shelf registration statement (S-3) filed November 2022.
- Shares will be sold on Nasdaq or other trading markets, subject to instructions and conditions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1689375/000110465923105351/0001104659-23-105351-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1689375/000110465923105351/tm2327232d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-105351

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer